Posts From King World News

GlobeImmune Hep B drug fails mid-stage study, shares plunge

Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company’s shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for hepatitis B treatments as hepatitis C drugs flood the market. Hepatitis

Yahoo must face email spying class action: U.S. judge

A U.S. judge ordered Yahoo Inc to face a nationwide class-action lawsuit accusing it of illegally intercepting the content of emails sent to Yahoo Mail subscribers from non-Yahoo Mail accounts, and using the information to boost advertising revenue. In a decision late Tuesday night, U.S. District Judge Lucy Koh in San Jose, California said people who sent emails to or received emails from Yahoo Mail subscribers since Oct. 2, 2011